2017 Annual Meeting | C11 - Neuromyelitis Optica Spectrum Disorders

Date Saturday 04/22/17

Time 10:30 AM - 12:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Dean M. Wingerchuk, MD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be able to understand the clinical, neuroimaging, laboratory, and pathologic characteristics of NMOSD; compare the utility of AQP4-IgG assay methods; recognize clinical characteristics associated with MOG-IgG; be able to discuss elements of the newly revised NMOSD diagnostic criteria; and describe approaches to prevention and treatment of acute NMOSD attacks.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
10:30 AM - 11:15 AM	Speaker	NMOSD: Pathogenesis and Clinical Diagnosis Brian G. Weinshenker, MD, F�鶹��ýӳ��
11:15 AM - 12:00 PM	Speaker	NMOSD: Current and Emerging Therapies and Strategies Dean M. Wingerchuk, MD, F�鶹��ýӳ��
12:00 PM - 12:30 PM	Speaker	Case-based Discussion

Faculty Disclosures
Dean M. Wingerchuk, MD, F�鶹��ýӳ��	Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Brian G. Weinshenker, MD, F�鶹��ýӳ��	Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.